The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Splice-switching antisense oligonucleotides as therapeutic drugs
Open accessAbstract
Splice-switching oligonucleotides (SSOs) are short, synthetic, antisense, modified nucleic acids that base-pair with a pre-mRNA and disrupt the normal splicing repertoire of the transcript by blocking the RNA-RNA base-pairing or protein-RNA binding interactions that occur between components of the splicing machinery and the pre-mRNA. Splicing of pre-mRNA is required for the proper expression of the vast majority of protein-coding genes, and thus, targeting the process offers a means to manipulate protein production from a gene. Splicing modulation is particularly valuable in cases of disease caused by mutations that lead to disruption of normal splicing or when interfering with the normal splicing process of a gene transcript may be therapeutic. SSOs offer an effective and specific way to target and alter splicing in a therapeutic manner. Here, we discuss the different approaches used to target and alter pre-mRNA splicing with SSOs. We detail the modifications to the nucleic acids that make them promising therapeutics and discuss the challenges to creating effective SSO drugs. We highlight the development of SSOs designed to treat Duchenne muscular dystrophy and spinal muscular atrophy, which are currently being tested in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
Pan, Q., Shai, O., Lee, L. J., Frey, B. J., & Blencowe, B. J. (2008) · Nature Genetics · doi:10.1038/ng.259 · Cited by 3,951
Spliceosome Structure and Function
Will, C. L., & Luhrmann, R. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003707 · Cited by 1,829
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Understanding alternative splicing: towards a cellular code
Matlin, A. J., Clark, F., & Smith, C. W. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1645 · Cited by 1,305
Mechanisms and Regulation of Alternative Pre-mRNA Splicing
Lee, Y., & Rio, D. C. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034316 · Cited by 1,291
The human splicing code reveals new insights into the genetic determinants of disease
Xiong, H. Y., Alipanahi, B., Lee, L. J., Bretschneider, H., Merico, D., Yuen, R. K. C., Hua, Y., Gueroussov, S., Najafabadi, H. S., Hughes, T. R., et al. (2015) · Science · doi:10.1126/science.1254806 · Cited by 1,220
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Correlation between severity and SMN protein level in spinal muscular atrophy
Lefebvre, S., Burlet, P., Liu, Q., Bertrandy, S., Clermont, O., Munnich, A., Dreyfuss, G., & Melki, J. (1997) · Nature Genetics · doi:10.1038/ng0797-265 · Cited by 1,100
Splicing regulation: From a parts list of regulatory elements to an integrated splicing code
Wang, Z., & Burge, C. B. (2008) · RNA · doi:10.1261/rna.876308 · Cited by 1,086
The Evolutionary Landscape of Alternative Splicing in Vertebrate Species
Barbosa-Morais, N. L., Irimia, M., Pan, Q., Xiong, H. Y., Gueroussov, S., Lee, L. J., Slobodeniuc, V., Kutter, C., Watt, S., Çolak, R., et al. (2012) · Science · doi:10.1126/science.1230612 · Cited by 1,063 · cited 1×
“Alternative splicing expands the diversity of the human proteome and thereby has been hypothesized to contribute to organismal complexity (17,18).”
BackgroundSplicing in disease: disruption of the splicing code and the decoding machinery
Wang, G.-S., & Cooper, T. A. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2164 · Cited by 1,050
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 961
Monani, U. R. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.7.1177 · Cited by 954
Barash, Y., Calarco, J. A., Gao, W., Pan, Q., Wang, X., Shai, O., Blencowe, B. J., & Frey, B. J. (2010) · Nature · doi:10.1038/nature09000 · Cited by 895
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Geary, R. S., Norris, D., Yu, R., & Bennett, C. F. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.008 · Cited by 845
Eteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C. F., & Krainer, A. R. (2011) · Nature · doi:10.1038/nature10485 · Cited by 741
Cartegni, L., & Krainer, A. R. (2002) · Nature Genetics · doi:10.1038/ng854 · Cited by 730
Phosphorothioates, Essential Components of Therapeutic Oligonucleotides
Eckstein, F. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0506 · Cited by 684
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., Platenburg, G. J., Sipkens, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011367 · Cited by 678
Morpholino antisense oligomers: the case for an RNase H-independent structural type
Summerton, J. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00150-5 · Cited by 664
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Sugarman, E. A., Nagan, N., Zhu, H., Akmaev, V. R., Zhou, Z., Rohlfs, E. M., Flynn, K., Hendrickson, B. C., Scholl, T., Sirko-Osadsa, D. A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.134 · Cited by 661
Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70211-x · Cited by 653
Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophy
Chiriboga, C. A., Swoboda, K. J., Darras, B. T., Iannaccone, S. T., Montes, J., De Vivo, D. C., Norris, D. A., Bennett, C. F., & Bishop, K. M. (2016) · Neurology · doi:10.1212/wnl.0000000000002445 · Cited by 612
Kolb, S. J., & Kissel, J. T. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2015.07.004 · Cited by 603
Physicochemical properties of phospborothioate oligodeoxynucleotides
Stein, C. A., Subasinghe, C., Shinozuka, K., & Cohen, J. S. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.8.3209 · Cited by 591
Hua, Y., Vickers, T. A., Okunola, H. L., Bennett, C. F., & Krainer, A. R. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.01.014 · Cited by 574
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy
Kashima, T., & Manley, J. L. (2003) · Nature Genetics · doi:10.1038/ng1207 · Cited by 546
McAndrew, P. E., Parsons, D. W., Simard, L. R., Rochette, C., Ray, P. N., Mendell, J. R., Prior, T. W., & Burghes, A. H. M. (1997) · The American Journal of Human Genetics · doi:10.1086/515465 · Cited by 543
Observational study of spinal muscular atrophy type I and implications for clinical trials
Finkel, R. S., McDermott, M. P., Kaufmann, P., Darras, B. T., Chung, W. K., Sproule, D. M., Kang, P. B., Foley, A. R., Yang, M. L., Martens, W. B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000741 · Cited by 528
Mendell, J. R., Goemans, N., Lowes, L. P., Alfano, L. N., Berry, K., Shao, J., Kaye, E. M., Mercuri, E., & for the Eteplirsen Study Group and Telethon Foundation DMD Italian Network (2016) · Annals of Neurology · doi:10.1002/ana.24555 · Cited by 518
Antisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506
Alter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S. D., Partridge, T. A., & Lu, Q. L. (2006) · Nature Medicine · doi:10.1038/nm1345 · Cited by 494
Deep learning of the tissue-regulated splicing code
Leung, M. K. K., Xiong, H. Y., Lee, L. J., & Frey, B. J. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu277 · Cited by 459
Singh, N. K., Singh, N. N., Androphy, E. J., & Singh, R. N. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1333-1346.2006 · Cited by 454
An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN
Lorson, C. L. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.2.259 · Cited by 435
Splicing-directed therapy in a new mouse model of human accelerated aging
Osorio, F. G., Navarro, C. L., Cadiñanos, J., López-Mejía, I. C., Quirós, P. M., Bartoli, C., Rivera, J., Tazi, J., Guzmán, G., Varela, I., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002847 · Cited by 432
Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Dominski, Z., & Kole, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8673 · Cited by 426
Childhood spinal muscular atrophy: controversies and challenges
Mercuri, E., Bertini, E., & Iannaccone, S. T. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70061-3 · Cited by 423
Lu, Q. L., Rabinowitz, A., Chen, Y. C., Yokota, T., Yin, H., Alter, J., Jadoon, A., Bou-Gharios, G., & Partridge, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406700102 · Cited by 402
Brody, E., & Abelson, J. (1985) · Science · doi:10.1126/science.3890181 · Cited by 401
Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogs
Yokota, T., Lu, Q., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S., & Hoffman, E. (2009) · Annals of Neurology · doi:10.1002/ana.21627 · Cited by 398
The Clothes Make the mRNA: Past and Present Trends in mRNP Fashion
Singh, G., Pratt, G., Yeo, G. W., & Moore, M. J. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-080111-092106 · Cited by 397
Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse
Mann, C. J., Honeyman, K., Cheng, A. J., Ly, T., Lloyd, F., Fletcher, S., Morgan, J. E., Partridge, T. A., & Wilton, S. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.42 · Cited by 388
Nowak, K. J., & Davies, K. E. (2004) · EMBO reports · doi:10.1038/sj.embor.7400221 · Cited by 357
Wirth, B., Brichta, L., Schrank, B., Lochmüller, H., Blick, S., Baasner, A., & Heller, R. (2006) · Human Genetics · doi:10.1007/s00439-006-0156-7 · Cited by 355
Differential SMN2 expression associated with SMA severity
Gavrilov, D. K., Shi, X., Das, K., Gilliam, T. C., & Wang, C. H. (1998) · Nature Genetics · doi:10.1038/3030 · Cited by 338
Determinants of Exon 7 Splicing in the Spinal Muscular Atrophy Genes, SMN1 and SMN2
Cartegni, L., Hastings, M. L., Calarco, J. A., de Stanchina, E., & Krainer, A. R. (2006) · The American Journal of Human Genetics · doi:10.1086/498853 · Cited by 306
Self-citationVoit, T., Topaloglu, H., Straub, V., Muntoni, F., Deconinck, N., Campion, G., De Kimpe, S. J., Eagle, M., Guglieri, M., Hood, S., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70195-4 · Cited by 306
Correction of disease-associated exon skipping by synthetic exon-specific activators
Cartegni, L., & Krainer, A. R. (2003) · Nature Structural Biology · doi:10.1038/nsb887 · Cited by 301
Antisense oligonucleotide pharmacokinetics and metabolism
Geary, R. S. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902877680 · Cited by 300
Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells
van Deutekom, J. C. T. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.15.1547 · Cited by 293
Prevalence of Duchenne and Becker Muscular Dystrophies in the United States
Romitti, P. A., Zhu, Y., Puzhankara, S., James, K. A., Nabukera, S. K., Zamba, G. K. D., Ciafaloni, E., Cunniff, C., Druschel, C. M., Mathews, K. D., et al. (2015) · Pediatrics · doi:10.1542/peds.2014-2044 · Cited by 290
Antisense oligonucleotides in therapy for neurodegenerative disorders
Evers, M. M., Toonen, L. J. A., & van Roon-Mom, W. M. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.008 · Cited by 286
Rigo, F., Chun, S. J., Norris, D. A., Hung, G., Lee, S., Matson, J., Fey, R. A., Gaus, H., Hua, Y., Grundy, J. S., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212407 · Cited by 283
Koller, E., Vincent, T. M., Chappell, A., De, S., Manoharan, M., & Bennett, C. F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr089 · Cited by 281
Campbell, M. A., & Wengel, J. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15048k · Cited by 279
Skordis, L. A., Dunckley, M. G., Yue, B., Eperon, I. C., & Muntoni, F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0633863100 · Cited by 274
Newborn and carrier screening for spinal muscular atrophy
Prior, T. W., Snyder, P. J., Rink, B. D., Pearl, D. K., Pyatt, R. E., Mihal, D. C., Conlan, T., Schmalz, B., Montgomery, L., Ziegler, K., et al. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33474 · Cited by 268
Cox, G. F., & Kunkel, L. M. (1997) · Current Opinion in Cardiology · doi:10.1097/00001573-199705000-00015 · Cited by 257
Wheeler, T. M., Lueck, J. D., Swanson, M. S., Dirksen, R. T., & Thornton, C. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33355 · Cited by 256
Dunckley, M. G., Manoharan, M., Villiet, P., Eperon, I. C., & Dickson, G. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.7.1083 · Cited by 255
The Spliceosome: The Ultimate RNA Chaperone and Sculptor
Papasaikas, P., & Valcárcel, J. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.11.003 · Cited by 252
A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse
Porensky, P. N., Mitrpant, C., McGovern, V. L., Bevan, A. K., Foust, K. D., Kaspar, B. K., Wilton, S. D., & Burghes, A. H. M. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr600 · Cited by 248
Lentz, J. J., Jodelka, F. M., Hinrich, A. J., McCaffrey, K. E., Farris, H. E., Spalitta, M. J., Bazan, N. G., Duelli, D. M., Rigo, F., & Hastings, M. L. (2013) · Nature Medicine · doi:10.1038/nm.3106 · Cited by 229
Self-citationMoulton, H. M., & Moulton, J. D. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.02.012 · Cited by 229
Advances in Duchenne muscular dystrophy gene therapy
van Deutekom, J. C. T., & van Ommen, G.-J. B. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1180 · Cited by 221
Defective control of pre–messenger RNA splicing in human disease
Chabot, B., & Shkreta, L. (2016) · Journal of Cell Biology · doi:10.1083/jcb.201510032 · Cited by 213
Haché, M., Swoboda, K. J., Sethna, N., Farrow-Gillespie, A., Khandji, A., Xia, S., & Bishop, K. M. (2016) · Journal of Child Neurology · doi:10.1177/0883073815627882 · Cited by 208
Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy
Mendell, J. R., & Lloyd‐Puryear, M. (2013) · Muscle & Nerve · doi:10.1002/mus.23810 · Cited by 202
Antisense-Induced Multiexon Skipping for Duchenne Muscular Dystrophy Makes More Sense
Aartsma-Rus, A., Janson, A. A. M., Kaman, W. E., Bremmer-Bout, M., van Ommen, G.-J. B., den Dunnen, J. T., & van Deutekom, J. C. T. (2004) · The American Journal of Human Genetics · doi:10.1086/381039 · Cited by 200
Structural basis of pre-mRNA splicing
Hang, J., Wan, R., Yan, C., & Shi, Y. (2015) · Science · doi:10.1126/science.aac8159 · Cited by 197
Cho, S., & Dreyfuss, G. (2010) · Genes & Development · doi:10.1101/gad.1884910 · Cited by 194
Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy
Taniguchi-Ikeda, M., Kobayashi, K., Kanagawa, M., Yu, C.-C., Mori, K., Oda, T., Kuga, A., Kurahashi, H., Akman, H. O., DiMauro, S., et al. (2011) · Nature · doi:10.1038/nature10456 · Cited by 189
Disease Mechanisms and Therapeutic Approaches in Spinal Muscular Atrophy
Tisdale, S., & Pellizzoni, L. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0417-15.2015 · Cited by 187
Antitumorigenic potential of STAT3 alternative splicing modulation
Zammarchi, F., de Stanchina, E., Bournazou, E., Supakorndej, T., Martires, K., Riedel, E., Corben, A. D., Bromberg, J. F., & Cartegni, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108482108 · Cited by 176
Intrathecal delivery of protein therapeutics to the brain: A critical reassessment
Calias, P., Banks, W. A., Begley, D., Scarpa, M., & Dickson, P. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.05.009 · Cited by 175
Heemskerk, H. A., de Winter, C. L., de Kimpe, S. J., van Kuik‐Romeijn, P., Heuvelmans, N., Platenburg, G. J., van Ommen, G. B., van Deutekom, J. C. T., & Aartsma‐Rus, A. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1288 · Cited by 173
Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth
Dewaele, M., Tabaglio, T., Willekens, K., Bezzi, M., Teo, S. X., Low, D. H. P., Koh, C. M., Rambow, F., Fiers, M., Rogiers, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82534 · Cited by 173
Targeting RNA splicing for disease therapy
Havens, M. A., Duelli, D. M., & Hastings, M. L. (2013) · WIREs RNA · doi:10.1002/wrna.1158 · Cited by 163
Self-citationBodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery
Aoki, Y., Yokota, T., Nagata, T., Nakamura, A., Tanihata, J., Saito, T., Duguez, S. M. R., Nagaraju, K., Hoffman, E. P., Partridge, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204638109 · Cited by 160
Lim, S. R., & Hertel, K. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107632200 · Cited by 159
The 3.8 Å structure of the U4/U6.U5 tri-snRNP: Insights into spliceosome assembly and catalysis
Wan, R., Yan, C., Bai, R., Wang, L., Huang, M., Wong, C. C. L., & Shi, Y. (2016) · Science · doi:10.1126/science.aad6466 · Cited by 159
Arechavala‐Gomeza, V., Graham, I. R., Popplewell, L. J., Adams, A. M., Aartsma-Rus, A. M., Kinali, M., Morgan, J. E., van Deutekom, J. C., Wilton, S. D., Dickson, G., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.061 · Cited by 152
Antisense‐mediated exon skipping: a therapeutic strategy for titin‐based dilated cardiomyopathy
Gramlich, M., Pane, L. S., Zhou, Q., Chen, Z., Murgia, M., Schötterl, S., Goedel, A., Metzger, K., Brade, T., Parrotta, E. I., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505047 · Cited by 150
An alternative splicing event amplifies evolutionary differences between vertebrates
Gueroussov, S., Gonatopoulos-Pournatzis, T., Irimia, M., Raj, B., Lin, Z.-Y., Gingras, A.-C., & Blencowe, B. J. (2015) · Science · doi:10.1126/science.aaa8381 · Cited by 148
Pathophysiological Insights Derived by Natural History and Motor Function of Spinal Muscular Atrophy
Farrar, M. A., Vucic, S., Johnston, H. M., et al. (2012) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2012.05.067 · Cited by 148
Hua, Y., Liu, Y. H., Sahashi, K., Rigo, F., Bennett, C. F., & Krainer, A. R. (2015) · Genes & Development · doi:10.1101/gad.256644.114 · Cited by 148
Induction of Antagonistic Soluble Decoy Receptor Tyrosine Kinases by Intronic PolyA Activation
Vorlová, S., Rocco, G., LeFave, C. V., Jodelka, F. M., Hess, K. C., Hastings, M. L., Henke, E., & Cartegni, L. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.009 · Cited by 147
Self-citationAn overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies
McClorey, G., & Wood, M. J. A. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.07.005 · Cited by 142
Anti-tumor activity of splice-switching oligonucleotides
Bauman, J. A., Li, S., Yang, A., Huang, L., & Kole, R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq731 · Cited by 141
Garanto, A., Chung, D. C., Duijkers, L., Corral-Serrano, J. C., Messchaert, M., Xiao, R., Bennett, J., Vandenberghe, L. H., & Collin, R. W. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw118 · Cited by 141
Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases
Southwell, A. L., Skotte, N. H., Bennett, C. F., & Hayden, M. R. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.09.001 · Cited by 140
Singh, N. N., Shishimorova, M., Cao, L., Gangwani, L., & Singh, R. N. (2009) · RNA Biology · doi:10.4161/rna.6.3.8723 · Cited by 139
Angelis, F. G. D., Sthandier, O., Berarducci, B., Toso, S., Galluzzi, G., Ricci, E., Cossu, G., & Bozzoni, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.142302299 · Cited by 136
Luco, R. F., & Misteli, T. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2011.03.004 · Cited by 134
Zhou, H., Janghra, N., Mitrpant, C., Dickinson, R. L., Anthony, K., Flynn, L. L., Eperon, I. C., Wilton, S. D., Morgan, J. E., & Muntoni, F. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.211 · Cited by 133
Hung, G., Xiao, X., Peralta, R. Q., Bhattacharjee, G., Murray, S., Norris, D., Guo, S., & Monia, B. P. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0443 · Cited by 131
Hinrich, A. J., Jodelka, F. M., Chang, J. L., Brutman, D., Bruno, A. M., Briggs, C. A., James, B. D., Stutzmann, G. E., Bennett, D. A., Miller, S. A., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505846 · Cited by 127
Self-citationExon identity crisis: disease-causing mutations that disrupt the splicing code
Sterne-Weiler, T., & Sanford, J. R. (2014) · Genome biology · doi:10.1186/gb4150 · Cited by 123
Takeshima, Y., Nishio, H., Sakamoto, H., Nakamura, H., & Matsuo, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117693 · Cited by 114
Oligonucleotide Therapeutics: Chemistry, Delivery and Clinical Progress
Sharma, V. K., & Watts, J. K. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.144 · Cited by 112
Rescue of cardiomyopathy through U7snRNA‐mediated exon skipping in Mybpc3‐targeted knock‐in mice
Gedicke, C., Behrens‐Gawlik, V., Reischmann, S., Geertz, B., Stimpel, D., Weinberger, F., Schlossarek, S., Précigout, G., Braren, I., Eschenhagen, T., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202168 · Cited by 111
Modulation of LMNA splicing as a strategy to treat prelamin A diseases
Lee, J. M., Nobumori, C., Tu, Y., Choi, C., Yang, S. H., Jung, H.-J., Vickers, T. A., Rigo, F., Bennett, C. F., Young, S. G., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85908 · Cited by 110
Identification of a Cis-acting Element for the Regulation ofSMN Exon 7 Splicing
Miyajima, H., Miyaso, H., Okumura, M., Kurisu, J., & Imaizumi, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200851200 · Cited by 104
Exon-Skipping Antisense Oligonucleotides to Correct Missplicing in Neurogenetic Diseases
Siva, K., Covello, G., & Denti, M. A. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0461 · Cited by 102
Arechavala‐Gomeza, V., Anthony, K., Morgan, J. E., & Muntoni, F. (2012) · Current Gene Therapy · doi:10.2174/156652312800840621 · Cited by 94
Lorenz, P. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.2.582 · Cited by 94
What Can We Learn From Clinical Trials of Exon Skipping for DMD?
Lu, Q., Çırak, S., & Partridge, T. A. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.6 · Cited by 92
Evers, M. M., Tran, H.-D., Zalachoras, I., Pepers, B. A., Meijer, O. C., den Dunnen, J. T., van Ommen, G. B., Aartsma-Rus, A. M., & van Roon‐Mom, W. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.019 · Cited by 88
Fu, X. (2004) · Cell · doi:10.1016/j.cell.2004.11.039 · Cited by 88
Mitrpant, C., Porensky, P. N., Zhou, H., Flynn, L. L., Muntoni, F., Fletcher, S., Wilton, S. D., & Burghes, A. H. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062114 · Cited by 84
Rudnik‐Schöneborn, S., Berg, C., Zerres, K., Betzler, C., Grimm, T., Eggermann, T., Eggermann, K., Wirth, R., Wirth, B., & Heller, R. (2009) · Clinical Genetics · doi:10.1111/j.1399-0004.2009.01200.x · Cited by 81
Antisense Oligonucleotide-Based Therapies for Diseases Caused by pre-mRNA Processing Defects
Rigo, F., Seth, P. P., & Bennett, C. F. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-1221-6_9 · Cited by 80
RNA repair restores hemoglobin expression in IVS2–654 thalassemic mice
Svasti, S., Suwanmanee, T., Fucharoen, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812436106 · Cited by 79
Merrick, D., Stadler, L. K. J., Larner, D. P., & Smith, J. D. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.001008 · Cited by 76
Development of Therapeutic Splice-Switching Oligonucleotides
Disterer, P., Kryczka, A., Liu, Y., Badi, Y. E., Wong, J. J., Owen, J. S., & Khoo, B. C. E. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.234 · Cited by 71
Clayton, N. P., Nelson, C. A., Weeden, T., Taylor, K. M., Moreland, R. J., Scheule, R. K., Phillips, L. A., Leger, A. J., Cheng, S. H., & Wentworth, B. M. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.57 · Cited by 70
Evers, M. M., Tran, H.-D., Zalachoras, I., Meijer, O. C., den Dunnen, J. T., van Ommen, G. B., Aartsma-Rus, A. M., & van Roon‐Mom, W. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0452 · Cited by 69
Graziewicz, M., Tarrant, T., Buckley, B., Roberts, J., Fulton, L. M., Hansen, H., Ørum, H., Kole, R., & Sazani, P. (2008) · Molecular Therapy · doi:10.1038/mt.2008.85 · Cited by 65
Osman, E. Y., Miller, M. R., Robbins, K. L., Lombardi, A., Atkinson, A. K., Brehm, A. J., & Lorson, C. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu198 · Cited by 64
Kang, J. K., Malerba, A., Popplewell, L. J., Foster, K., & Dickson, G. (2010) · Molecular Therapy · doi:10.1038/mt.2010.212 · Cited by 61
Keil, J. M., Seo, J., Howell, M. D., Hsu, W. H., Singh, R. N., & DiDonato, C. J. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.23 · Cited by 60
Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing
Peacey, E., Rodríguez, L. C. D. L. C., Liu, Y., & Wolfe, M. S. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks710 · Cited by 58
Skipping Multiple Exons of Dystrophin Transcripts Using Cocktail Antisense Oligonucleotides
Echigoya, Y., & Yokota, T. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0451 · Cited by 57
Pathological impact of SMN2 mis‐splicing in adult SMA mice
Sahashi, K., Ling, K., Hua, Y., Wilkinson, J. E., Nomakuchi, T. T., Rigo, F., Hung, G., Xu, D. S., Jiang, Y., Lin, R. Z., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302567 · Cited by 55
Splicing modulation therapy in the treatment of genetic diseases
Aartsma-Rus, A. M., Arechavala‐Gomeza, V., & Khoo, B. C. E. (2014) · The Application of Clinical Genetics · doi:10.2147/tacg.s71506 · Cited by 51
Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model
Bestas, B., Moreno, P. M. D., Blomberg, K. E. M., Mohammad, D. K., Saleh, A. F. A., Sütlü, T., Nordin, J. Z., Guterstam, P., Gustafsson, M. O., Kharazi, S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76175 · Cited by 49
Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice
Han, G., Gu, B., Cao, L., Gao, X., Wang, Q., Seow, Y., Zhang, N., Wood, M. J. A., & Yin, H. (2016) · Nature Communications · doi:10.1038/ncomms10981 · Cited by 48
Owen, L. A., Uehara, H., Cahoon, J. M., Huang, W. C., Simonis, J. M., & Ambati, B. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033576 · Cited by 45
Wu, B., Cloer, C., Lu, P., Milazi, S., Shaban, M., Shah, S. N., Marston-Poe, L., Moulton, H. M., & Lu, Q. L. (2014) · Gene Therapy · doi:10.1038/gt.2014.53 · Cited by 44
Safety Pharmacology and Genotoxicity Evaluation of AVI-4658
Sazani, P., Weller, D. L., & Shrewsbury, S. B. (2010) · International Journal of Toxicology · doi:10.1177/1091581809359206 · Cited by 44
Overview of Alternative Oligonucleotide Chemistries for Exon Skipping
Saleh, A. F. A., Arzumanov, A. A., & Gait, M. J. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-767-5_23 · Cited by 44
Larson, J. L., Silver, A. J., Chan, D., Borroto, C., Spurrier, B., & Silver, L. M. (2015) · BMC Medical Genetics · doi:10.1186/s12881-015-0246-2 · Cited by 42
Negishi, Y., Ishii, Y., Shiono, H., Akiyama, S., Sekine, S., Kojima, T., Mayama, S., Kikuchi, T., Hamano, N., Endo‐Takahashi, Y., et al. (2014) · Molecular Pharmaceutics · doi:10.1021/mp4004755 · Cited by 41
Nielsen, T. Ø., Sorensen, S., Dagnæs‐Hansen, F., Kjems, J., & Sørensen, B. S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.247 · Cited by 40
Gene-targeting pharmaceuticals for single-gene disorders
Beaudet, A. L., & Meng, L. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv476 · Cited by 40
Disterer, P., Al‐Shawi, R., Ellmerich, S., Waddington, S. N., Owen, J. S., Simons, J. P., & Khoo, B. C. E. (2013) · Molecular Therapy · doi:10.1038/mt.2012.264 · Cited by 37
Uehara, H., Cho, Y., Simonis, J., Cahoon, J. M., Archer, B. J., Luo, L., Das, S. K., Singh, N., Ambati, J., & Ambati, B. K. (2012) · The FASEB Journal · doi:10.1096/fj.12-213835 · Cited by 34
Koebis, M., Kiyatake, T., YAMAURA, H., et al. (2013) · Scientific Reports · doi:10.1038/srep02242 · Cited by 28
Mourich, D. V., Oda, S. K., Schnell, F. J., Crumley, S. L., Hauck, L., Moentenich, C. A., Marshall, N. B., Hinrichs, D. J., & Iversen, P. L. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0449 · Cited by 28
Lu‐Nguyen, N., Jarmin, S., Saleh, A. F. A., Popplewell, L. J., Gait, M. J., & Dickson, G. (2015) · Molecular Therapy · doi:10.1038/mt.2015.88 · Cited by 27
Gene and splicing therapies for neuromuscular diseases
Goyenvalle, A. (2015) · Frontiers in bioscience · doi:10.2741/4367 · Cited by 26
Verhaart, I. E. C., Winter, C. L. T.-D., Karnaoukh, T. G., Kolfschoten, I., de Kimpe, S. J., van Deutekom, J. C. T., & Aartsma-Rus, A. M. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0398 · Cited by 22
An update on RNA-targeting therapies for neuromuscular disorders
Jirka, S. M. G., & Aartsma-Rus, A. M. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000235 · Cited by 22
Clayton, N. P., Nelson, C. A., Weeden, T., Taylor, K. M., Moreland, R. J., Scheule, R. K., Leger, A. J., Phillips, L. A., Cheng, S. H., & Wentworth, B. M. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.12.055 · Cited by 20
Salewsky, B., Hildebrand, G., Rothe, S., Parplys, A. C., Radszewski, J., Kieslich, M., Wessendorf, P., Krenzlin, H., Borgmann, K., Nussenzweig, A., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.144 · Cited by 11
Cited by
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Targeting RNA structures with small molecules
Childs-Disney, J. L., Yang, X., Gibaut, Q. M. R., Tong, Y., Batey, R. T., & Disney, M. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00521-4 · Cited by 587
RNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
Urbanski, L. M., Leclair, N., & Anczuków, O. (2018) · WIREs RNA · doi:10.1002/wrna.1476 · Cited by 389
Metadata
- Authors
- Havens, M. A., & Hastings, M. L.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06-10
- Volume
- 44
- Issue
- 14
- Pages
- 6549-6563
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2411634967
- Cited by
- 538
- References
- 153
- FWCI
- 19.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.